Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations




Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities.

“I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive experience in managing drug candidates through the clinic, across a variety of therapeutic areas, will benefit us greatly as we move our neuroregenerative candidates through clinical studies and assemble the data packages needed for eventual NDA submissions.”

“I am delighted to be joining the Pipeline team, just as the company’s lead program, PIPE-505 for sensorineural hearing loss, is progressing through a proof-of-concept Phase 1/2a study, and as PIPE-307 enters the clinic, both candidates with great potential to help patients with unmet medical needs,” said Ms. Iwashita. “I believe Pipeline Therapeutics is well-positioned to transform the current treatment of neurological disorders, based on its exciting and proprietary technology covering synaptogenesis, remyelination and axonal repair.”

Julie most recently served as Vice President of Clinical Operations for Cirius Therapeutics, a clinical-stage pharmaceutical company focused on the development of treatments for liver and metabolic diseases. Previously she served as Executive Director, Clinical Operations at Kodiak Sciences Inc., (NASDAQ: KOD). Prior to Kodiak, Julie served as Executive Director of Clinical Development at Laguna Pharmaceuticals and before that at Sorbent Therapeutics. Prior to Sorbent, Julie was Senior Director of Clinical Development at MAP Pharmaceuticals, Proteolix, Inc. and Affymax, Inc. (OTCMKTS: AFFY). Julie has served as a consultant for multiple private and public biotech companies exploring neurological disorders including age-related macular degeneration, spinal cord injury, and migraine headaches. She has also managed clinical programs at Genitope, Aviron, Amgen and Syntex in therapeutic areas including renal, cardiovascular, and oncology.

Julie holds a bachelor’s degree in human biology from Stanford University.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

Contacts

Company Contact: 

Carmine Stengone 

President and CEO 

info@pipelinetherapeutics.com

Investor Contact: 

Laurence Watts 

619-916-7620 

laurence@gilmartinir.com

North America Automated Dispensing Systems Market Forecast to 2027 Featuring Cerner Corporation, Capsa Healthcare, OMNICELL., ARxIUM, and Accu-Chart Plus Healthcare Systems – ResearchAndMarkets.com




North America Automated Dispensing Systems Market Forecast to 2027 Featuring Cerner Corporation, Capsa Healthcare, OMNICELL., ARxIUM, and Accu-Chart Plus Healthcare Systems – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North America Automated Dispensing Systems Market Forecast to 2027 – COVID-19 Impact and Regional Analysis by Operation; Application; End User, and Country” report has been added to ResearchAndMarkets.com’s offering.

North America automated dispensing systems market accounted for US$814.69Mn in 2019 and is anticipated to grow at a CAGR of 7.8% to account for US$1,479.76 Mn by 2027

The North America automated dispensing systems market, based on operation, is segmented into decentralized systems and centralized systems. The centralized systems segment held the larger share of the market in 2019. In the wake of the increasing incidence of deaths caused by medication errors, government bodies across the globe have started encouraging pharmacies and hospitals to implement advanced technologies for dispensing accurate dosage of medicines to treat medical conditions more effectively.

Hospitals are adopting advanced technologies such as automated dispensing systems to store, dispense, and track medicines in order to improve efficiency and patient safety. These systems enhance the efficiency of medication distribution and also minimize the medication errors in hospitals. As the majority of geriatric population suffers from various chronic diseases, there is increase in the demand for advanced medication.

North America automated dispensing systems market is expected to grow owing to factors such as increasing adoption of processes to control inventory costs, rise in awareness towards health and safety for reduction of medication errors, improving healthcare infrastructure and technological advancements during the forecast period. However, problems associated with automated dispensing systems like excessive use of overrides in cabinets with patient profiling and placing the patient at risk of allergic reactions are likely to pose a negative impact on the market growth.

Cerner Corporation, Capsa Healthcare, OMNICELL INC., ARxIUM, and Accu-Chart Plus Healthcare Systems are among the leading companies operating in the North America automated dispensing systems market.

Key Topics Covered:

1. Introduction

1.1 Scope of the Study

1.2 Research Report Guidance

1.3 Market Segmentation

2. North America Automated Compounding Systems Market – Key Takeaways

3. Research Methodology

4. North America Automated Compounding Systems Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinion

5. North America Automated Compounding Systems Market – Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Growing Adoption of Chemotherapy and Personalized Medication

5.1.2 Rising Need to Minimize Medication Errors

5.2 Key Market Restraints

5.2.1 High Cost of the Automated Compounding Systems

5.3 Key Market Opportunities

5.3.1 Increasing Awareness in Pharmacists

5.4 Future Trends

5.4.1 Introduction of Novel Robotic Technology Automation in Compounding Systems

5.5 Impact Analysis

6. Automated Compounding Systems Market – North America Analysis

6.1 North America Automated Compounding Systems Market Revenue Forecasts and Analysis

7. North America Automated Compounding Systems Market Analysis and Forecasts To 2027 – By Product Type

7.1 Overview

7.2 North America Automated Compounding Systems Market, By Product Type 2019 & 2027 (%)

7.3 Gravimetric Automated Compounding Systems

7.4 Volumetric Automated Compounding Systems

8. North America Automated Compounding Systems Market Analysis – By End-User

8.1 Overview

8.2 North America Automated Compounding Systems Market, By End-User 2019-2027 (%)

8.3 Hospitals

8.4 Chemotherapy Centers

9. Automated Compounding Systems Market Revenue and Forecasts To 2027 – Geographical Analysis

10. Impact Of COVID-19 Pandemic on North America Automated Compounding Systems Market

11. Company Profiles

• Cerner Corporation
• Capsa Healthcare
• OMNICELL INC.
• ARxIUM
• Accu-Chart Plus Healthcare Systems

For more information about this report visit https://www.researchandmarkets.com/r/33elk8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Europe Cancer Vaccines Market Forecast to 2027 with COVID-19 Impact Insights – ResearchAndMarkets.com




Europe Cancer Vaccines Market Forecast to 2027 with COVID-19 Impact Insights – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Europe Cancer Vaccines Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Technology; Type; Indication; End User, and Country and Country” report has been added to ResearchAndMarkets.com’s offering.

Cancer Vaccines Market for Dendritic Cells Cancer Vaccines Segment to Grow at Fastest CAGR during Forecast Period

Te market is expected to reach to reach US$4,680.79 million by 2027

Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines. The in recombinant cancer vaccines segment held the largest share of the market in 2019. Moreover, recombinant cancer vaccines is estimated grow at the highest CAGR in the market during the forecast period.

Market growth in Europe Cancer Vaccines is mainly due to factors such as increasing prevalence of cancer and rising government initiatives to prevent cancer. However, challenges such as costly costs in the cancer vaccine industry restrict the growth of the market.

AstraZeneca, GlaxoSmithKline plc., Aduro Biotech Inc, Pfizer Inc., Sanofi, Bristol-Myers Squibb, Moderna, Inc., OncBioMune Pharmaceuticals Inc., MaxiVAX, Nouscom are among the leading companies operating in the Cancer Vaccines Market.

Key Topics Covered:

1. Introduction

2. Key Takeaways

3. Research Methodology

4. Cancer Vaccines Market Landscape

4.1. Overview

4.2. Pest Analysis

4.3. Expert Opinions

5. Cancer Vaccines Market – Key Market Dynamics

5.1. Key Market Drivers

5.2. Key Market Restraints

5.3. Key Market Opportunities

5.4. Future Trends

5.5. Impact Analysis Of Drivers And Restraints

6. Cancer Vaccines Market – Europe Market Analysis

6.1. Cancer Vaccines – Europe Market Overview

6.2. Cancer Vaccines – Europe Market And Forecast To 2027

6.3. Market Positioning/Market Share

7. Cancer Vaccines Market – Revenue And Forecasts To 2027 – Technology

7.1. Overview

7.2. Technology Market Forecasts And Analysis

7.3. Dendritic Cells Cancer Vaccines

7.4. Recombinant Cancer Vaccines

7.5. Antigen Cancer Vaccines

7.6. Whole Cell Cancer Vaccines

7.7. Viral Vector Cancer Vaccines

8. Cancer Vaccines Market – Revenue And Forecasts To 2027 – Type

8.1. Overview

8.2. Type Market Forecasts And Analysis

8.3. Preventive Cancer Vaccines

8.4. Therapeutic Cancer Vaccines

9. Cancer Vaccines Market – Revenue And Forecasts To 2027 – Indication

9.1. Overview

9.2. Indication Market Forecasts And Analysis

9.3. Cervical Cancer

9.4. Prostate Cancer

9.5. Other Indications

10. Cancer Vaccines Market – Revenue And Forecasts To 2027 – End User

10.1. Overview

10.2. End User Market Forecasts And Analysis

10.3. Pediatrics

10.4. Adults

11. Cancer Vaccines Market Revenue And Forecasts To 2027 – Country Analysis

12. Impact Of Covid-19 Pandemic On Global Cancer Vaccines Market

12.1 North America

12.2 Europe

12.3 Asia-Pacific

12.4 Rest Of The World

13. Industry Landscape

13.1. Mergers And Acquisitions

13.2. Agreements, Collaborations And Joint Ventures

13.3. New Product Launches

13.4. Expansions And Other Strategic Developments

14. Cancer Vaccines Market, Key Company Profiles

• AstraZeneca
• GlaxoSmithKline plc.
• Aduro Biotech Inc
• Pfizer Inc.
• Sanofi
• Bristol-Myers Squibb
• Moderna, Inc.
• OncBioMune Pharmaceuticals Inc.
• MaxiVAX
• Nouscom

For more information about this report visit https://www.researchandmarkets.com/r/9gs550

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Discovery Life Sciences and Scientist.com Partner to Advance Liquid Biopsy Development and Immunotherapy Research




Discovery Life Sciences and Scientist.com Partner to Advance Liquid Biopsy Development and Immunotherapy Research

Discovery’s TruSight Oncology 500 (TSO500) solid tumor FFPE and ctDNA services now available through Scientist.com

SAN DIEGO–(BUSINESS WIRE)–#fasterscience–Scientist.com, the healthcare industry’s leading marketplace for outsourced research, and Discovery Life Sciences™ (Discovery), a global leader in biospecimen solutions, genomic, cell and immunohistochemistry (IHC) services, have partnered to offer researchers online access to Illumina’s TruSight™ Oncology 500 (TSO500) technology. The TSO500 technology was recently added to HudsonAlpha Discovery™, Discovery’s highly regarded sequencing and bioinformatics laboratory.

“HudsonAlpha Discovery’s TSO500 platform combined with Discovery Life Sciences’ comprehensive biospecimen solutions, which are also available through Scientist.com, will accelerate immuno-oncology and liquid biopsy biomarker studies through delivery of actionable NGS data across patient-matched tumor and plasma biospecimens,” stated Kevin Lustig, PhD, CEO and founder of Scientist.com. “This cutting-edge technology is now available to all Scientist.com users under one pre-established legal agreement, accelerating preclinical research and enabling faster science.”

Illumina’s TSO500 solid Tumor (FFPE) and ctDNA technology enables genomic characterization across a broad range of tumor types through the identification of somatic variants from DNA and RNA, including critical immuno-oncology SNV, InDel, CNV and fusion biomarkers, as well as microsatellite instability (MSI) and tumor mutational burden (TMB).

“Our services are optimized for efficiency to enable rapid delivery of the valuable NGS data that only TSO500 provides across matched FFPE and plasma samples at any scale,” stated Dr. Shawn Levy, PhD, Chief Scientific Officer at Discovery Life Sciences. “By making these new services available on Scientist.com, we will advance biomarker programs and allow researchers to more quickly develop and validate new immunotherapeutics, liquid biopsy diagnostics and companion diagnostics.”

To learn more about applications for TSO500 technology watch the recent webinar, High Sensitivity TSO500 Detection of Somatic Variants in Matched FFPE and Plasma: Implications for Liquid Biopsy Biomarker Evaluations, featuring Dr. Levy of Discovery Life Sciences.

About Discovery Life Sciences

Discovery Life Sciences is the global market leader in biospecimen analysis, procurement, distribution, and scientific services for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s globally recognized sequencing and bioinformatics division that leverages the most current genomic research technologies to comprehensively support discovery, translational, and clinical research. Driven by science, the Discovery team engages with customers in an innovative, consultative approach to overcoming obstacles and reaching a faster end result. We are Science at your Service™! For more information, visit dls.com.

About Scientist.com

Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO), and the US National Institutes of Health (NIH).

Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook, and Instagram

Contacts

Sean Preci

Director of Communications

+1 858 455-1300 ext. 401

marketing@scientist.com

Hy-Vee Launches New Pharmacy Benefits Manager Subsidiary




Hy-Vee Launches New Pharmacy Benefits Manager Subsidiary

Vivid Clear Rx to offer PBM services to help employees better manage health care costs

WEST DES MOINES, Iowa–(BUSINESS WIRE)–Hy-Vee, Inc. announces today the launch of its newest subsidiary, Vivid Clear Rx. The new subsidiary will offer affordable pharmacy benefit management services to Hy-Vee’s more than 88,000 employees as well as other employers looking to maximize their employee benefits spending.

“Health care spending continues to be a leading concern for employers across the country, and every business wants to make sure they are providing the best benefits for their employees at the best value,” said Randy Edeker, Hy-Vee chairman, CEO and president. “With the launch of Vivid Clear Rx, we’re leveraging our experience in the pharmacy industry and the expertise we’ve gained from serving millions of pharmacy patients to help other employers make the most of every health care dollar they’re investing in their employees.”

Vivid Clear Rx will offer a full range of flexible pharmacy benefit management services, powered by RxSense’s RxAgile enterprise technology, which will provide clarity to those utilizing the company’s services. RxSense is providing Vivid Clear Rx with a full-service suite of modules for pharmacy benefit management that will supplement assets that Hy-Vee already owns and operates. RxSense’s analytics product RxIQ will provide Vivid Clear Rx with real-time health plan performance insights through customizable data dashboards; financial, operational and clinical action alerts; and the ability to quickly evaluate data by claim type, pharmacy or geography.

“We are very excited to offer services in partnership with RxSense, as we know their data platform will help businesses, including Hy-Vee, make even better decisions when it comes to employee benefits and pharmacy spending,” said Mike Agostino, senior vice president for pharmacy business development at Hy-Vee and president of Vivid Clear Rx. “We look forward to helping Hy-Vee and many other employers around the country gain better insights into their pharmacy benefits spending as well as bring greater value to their health care programs.”

To learn more about Vivid Clear Rx and its service offerings, visit www.vividclearrx.com.

Hy-Vee, Inc., the parent company of Vivid Clear Rx, is an employee-owned corporation operating more than 275 retail stores across eight Midwestern states with sales of $10 billion annually. The supermarket chain is synonymous with quality, variety, convenience, healthy lifestyles, culinary expertise and superior customer service. Hy-Vee ranks in the Top 10 Most Trusted Brands and has been named one of America’s Top 5 favorite grocery stores. The company’s more than 88,000 employees provide “A Helpful Smile in Every Aisle” to customers every day. For additional information, visit www.hy-vee.com.

Contacts

Media Contact:
Tina Potthoff

Senior Vice President, Communications

Office: (515) 559-5770

Mobile: (515) 975-9211

tpotthoff@hy-vee.com

Global Precision Medicines Market Insights to 2028 – Impact of COVID-19 – ResearchAndMarkets.com




Global Precision Medicines Market Insights to 2028 – Impact of COVID-19 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Precision Medicines – Market and Technology to 2028” report has been added to ResearchAndMarkets.com’s offering.

The study period of this report is from 2018-2020 and a forecast period of 2020-2028. The CAGR of this market is expected to be 11% during the forecast period. The report is segmented by the technology, region and application.

Precision medicine is a synonym for personalized medicine. This technology proposes the customization of healthcare. The diagnostics are designed for a specific individual rather than using a generalised clinical approach. It divides a broad class of subjects by their susceptibility to a particular disease or response to a specific treatment in order to go further with their diagnostic analysis. It makes use of system biology and panomics to recognise the root cause of the disease at a molecular level which further helps them with recognising the correct way of treatment.

The key driver for this market is the use of novel technology to personalize medicine and hereby understand individual genes, surrounding environment, and lifestyle specific to a patient. Moreover, the growing medical advancements in the field of gene therapy coupled with several medical benefits is expected to propel the market. Accessibility to large-scale human genotype database helps expand the reach of PM and hereby accelerates the market growth positively.

This report takes segments the global precision medicines market into technology, region and application. It delves into all the technological advancements of this sector accompanied by the end-user applications of this market that propel the market growth of this sector.

North America is expected to dominate the global market owing to the presence of the key players in this region. Initiatives like GENIE launched by AACR coupled with increased research funding in this sector propels the growth of this sector. In the European sector, U.K is the major contributor to this market, due to rising incidents of cancer and government regulations that support the growth of this sector. Moreover, the emergence of big data further promotes the growth of this segment.

Reasons to buy:

• New players of this market can use this report to understand the drivers, restraints, and challenges that are expected to influence the market.
• Existing players can use this report to plan both near term and future term strategies since the forecast period ranges up to 2028.
• Existing players can use this report to study the opportunities offered by this market which could help them expand their existing enterprise.
• Technology innovators can use this report to study the existing technology and the demand of the same according to which they could optimise the drawbacks.
• The impact of COVID-19 has been provided in this report along with the shifting market dynamics that could help new players with creating a post-pandemic plan.
• The sales team could make use of this report to gain a customer-based perspective with respect to demographics.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Current Market Overview of the Global Precision Medicines Market

4 Current Technology Trends in the Global Precision Medicines

5 Market Segmentation

5.1 By Technology

5.2 By Region

5.3 By Application

6 Market Analysis

6.1 Introduction

6.2 Porter’s 5 Forces Analysis

6.2.1 Competitive Rivalry

6.2.2 Supplier Power

6.2.3 Buyer Power

6.2.4 Threat of Substitution

6.2.5 Threat of New Entry

6.3 PEST

6.4 Market Dynamics

6.4.1 Drivers

6.4.2 Restraints

6.4.3 Challenges

6.5 Country Analysis

6.5.1 United States

6.5.2 Canada

6.5.3 France

6.5.4 Germany

6.5.5 Spain

6.5.6 Portugal

6.5.7 Denmark

6.5.8 Netherlands

6.5.9 Sweden

6.5.10 Finland

6.5.11 United Kingdom

6.5.12 Switzerland

6.5.13 Italy

6.5.14 Japan

6.5.15 Israel

6.5.16 Turkey

6.5.17 Australia

6.5.18 China

6.5.19 Malaysia

6.5.20 Brazil

7 Forecast Global Precision Medicines Market by Technology to 2028

7.1 Introduction

7.2 Global Precision Medicines Market by Technology overview

7.3 Global Precision Medicines Market By Technology (By Application)

7.3.1 Genomics

7.3.2 Transcriptomics

7.3.3 Epigenomics

8 Forecast Global Precision Medicines Market by Region to 2028

8.1 Introduction

8.2 Global Precision Medicines Market by Region overview

8.3 Global Precision Medicines Market By Region (By Technology)

8.3.1 North America

8.3.2 Europe

8.3.3 APAC

8.3.4 Middle East

8.3.5 Rest of the World

9 Forecast Global Precision Medicine Market by Application to 2028

9.1 Introduction

9.2 Global Precision Medicine Market by Application Overview

9.3 Global Precision Medicine Market By Application (By End User)

9.3.1 Oncology

9.3.2 CNS

9.3.3 Immunology

9.3.4 Respiratory Medicine

9.3.5 Infections

9.3.6 Others

10 Opportunity Analysis Global Precision Medicine Market

11 Events based forecast for the Global Precision Medicine Market to 2028

11.1 Introduction

11.2 Events forecast factors

11.3 Global Market

11.4 Events Based Forecast- Scenario 1

11.5 Events Based Forecast- Scenario 2

12 Corona Impact

13 Conclusions and recommendations

14 Company Profiles

15 About the publisher

16 Appendices

For more information about this report visit https://www.researchandmarkets.com/r/hwhlx8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900